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ABSTRACT 
Introduction 
Intravenous (IV) fluid is a key intervention in the management of septic shock. The benefits 
and harms of lower versus higher fluid volumes are unknown and clinical equipoise exists. 
We describe the protocol and detailed statistical analysis plan for the Conservative versus 
Liberal Approach to fluid therapy of Septic Shock in the Intensive Care (CLASSIC) trial. The 
aim of the CLASSIC trial is to assess benefits and harms of IV fluid restriction versus 
standard care in adult intensive care unit (ICU) patients with septic shock. 
 
Methods 
CLASSIC trial is an investigator-initiated, international, randomised, stratified, and analyst-
blinded trial. We will allocate 1554 adult patients with septic shock, who are planned to be or 
are admitted to an ICU, to IV fluid restriction versus standard care. The primary outcome is 
mortality at day 90. Secondary outcomes are serious adverse events, serious adverse 
reactions, days alive at day 90 without life support, days alive and out of hospital at day 90, 
and mortality, health-related quality of life, and cognitive function at 1 year. We will conduct 
the statistical analyses according to a pre-defined statistical analysis plan, including three 
interim analyses. For the primary analysis we will use logistic regression adjusted for the 
stratification variables comparing the two interventions in the intention-to-treat population.  
 
Discussion 
The CLASSIC trial results will provide important evidence to guide clinicians’ choice 
regarding IV fluid therapy in adults with septic shock. 
 
INTRODUCTION 
Intravenous (IV) fluid therapy is a mainstay intervention in the treatment of sepsis. However, 
international guidelines lack firm evidence for the optimal volume.1 Patients with septic shock 
in the intensive care unit (ICU) may receive IV fluids according to several indications: 2,3 to 
improve hemodynamics, replace fluid loss, correct electrolyte imbalance or dehydration, as 
maintenance fluid, as a carrier for medication, or as nutrition.4–6 Administration of IV fluids in 
the ICU may lead to over-hydration, which has been associated with adverse outcomes,7–9 
and data from randomised clinical trials (RCTs) both in a pre-clinical10 and a clinical 
setting11–15 have raised concerns about harms from higher IV fluid volumes.  
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In a landmark trial in African children with infection and circulatory impairment, increased 
mortality was observed in children who received fluid boluses as compared to those who did 
not.12 Other African trials in adult patients with infection and hypotension have shown higher 
mortality in patients who received higher IV fluid volumes; one trial was stopped early after 
all patients with hypoxemic respiratory failure died,14 another trial, in which patients with 
severe respiratory failure were excluded, showed higher mortality in patients who received 
higher IV fluid volumes as part of a complex protocol.15 As most patients with septic shock in 
Europe are cared for in ICUs, extrapolating results from trials conducted in resource-limited 
settings is challenging.  
 
In the CLASSIC pilot trial,11 a protocol aiming at restricting IV resuscitation fluid volumes 
compared with standard care in adult ICU patients with septic shock was feasible and 
resulted in lower resuscitation fluid volumes given in the first 5 days and during the entire 
ICU stay. The trial showed no statistically significant difference in mortality, serious adverse 
reactions, ischemia, total fluid input, or fluid balances. Fewer patients had worsening of 
acute kidney injury (AKI) among those who received less fluid. However, this was an 
exploratory outcome measure.11   
 
In a systematic review of RCTs aiming at separation in IV fluid volumes in adult patients with 
sepsis, we have currently identified 8 trials including a total of 524 patients; all trials were 
judged to have overall high risk of bias. We found very low quantity and certainty of the 
evidence for lower versus higher fluid volumes across all patient-important outcomes 
(Meyhoff 2019, in preparation)16 
 
Altogether, there is a need for high-quality data from RCTs to inform the decision on fluid 
volume strategies in septic shock.  
 
The aim of the CLASSIC trial is to assess the effects of IV fluid restriction versus standard 
care on patient-important outcome measures in adult ICU patients with septic shock. We 
hypothesise that fluid restriction will improve patient-important outcomes. In this manuscript, 
we outline the rationale, methods and the detailed statistical analysis plan.  
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METHODS 
Trial design 
The CLASSIC trial is an investigator-initiated, pragmatic, international, parallel-grouped, 
centrally randomised, stratified, analyst-blinded trial with adequate allocation sequence 
generation and allocation concealment.  
Trial conduct 
The protocol has been prepared according to the Standard Protocol Items: 
Recommendations for Interventional Trials (SPIRIT) guidelines.17 The trial will adhere to this 
protocol, the Helsinki Declaration in its latest version,18 the international guidelines for good 
clinical practice (GCP)19, and the national laws in the participating countries. 
Randomisation 
Eligible patients fulfilling all inclusion criteria and no exclusion criteria are randomised 1:1 
using a centralised web-based system according to a computer-generated allocation 
sequence list, the stratification variables and varying block sizes. The allocation sequence 
list and block sizes are only known by the data manager at Copenhagen Trial Unit, and 
remain concealed from the investigators until the last patient has completed follow-up. 
 
Blinding 
The trial intervention is not blinded for investigators, clinical staff and patients, as blinding of 
IV fluid restriction versus standard care is not feasible. The statistician assessing all 
outcomes will be masked for the allocation. The data for 90-day and 1-year mortality will be 
collected from electronic patient records or central national registries in most participating 
countries. The remaining outcomes will be provided by local investigators, who are not 
blinded for the intervention, by entering data from patients’ files.  The management 
committee will write the preliminary abstract with the group allocation masked; this abstract 
will be published as a supplement to the primary trial report.20,21 
Inclusion criteria 
Patients must fulfil all the inclusion criteria; 
 Age ≥18 years  
 Admitted or planned admitted to the ICU regardless of trial participation 
 Septic shock defined according to the Sepsis-3 criteria:22 
o Suspected or confirmed site of infection or positive blood culture AND 
o On-going infusion of vasopressor/inotrope agent to maintain a mean arterial 
blood pressure of 65 mmHg or above AND 
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o Lactate of 2 mmol/L or above in any plasma sample performed within the last 
3-hours 
 At least 1 L of IV fluid administered (all crystalloids, colloids or blood products 
including that given with medication and nutrition) in the last 24 hours prior to 
screening 
A detailed description of the inclusion criteria is available in Supplementary Appendix 1.  
Exclusion criteria 
Patients who fulfil all inclusion criteria and one or more of the exclusion criteria below will be 
excluded;  
 Septic shock for more than 12 hours at the time of screening  
 Life-threatening bleeding  
 Acute burn injury of more than 10% of the body surface area  
 Known pregnancy  
 Consent not obtainable as per the model approved for the specific site 
A detailed description of the exclusion criteria is available in Supplementary Appendix 2. 
Trial interventions 
The CLASSIC intervention period is the time spent in ICU from randomisation to a maximum 
of 90 days. If a patient is discharged and readmitted to a CLASSIC ICU within the 90-day 
period, the allocated fluid intervention continues.  
 
IV fluid restriction group 
No IV fluids should be given unless one of the below extenuating circumstances occurs; in 
these cases, IV fluid may be given in measured amounts: 
1. In case of severe hypoperfusion or severe circulatory impairment defined by either: 
o Lactate 4 mmol/L or above 
OR  
o Mean arterial blood pressure below 50 mmHg (with or without 
vasopressor/inotrope) OR 
o Mottling beyond the kneecap (mottling score >2, Supplementary Appendix 3)  
OR 
o Urinary output less 0.1mL/kg bodyweight/h, but only in the first 2 hours after 
randomisation 
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A bolus of 250-500 ml of IV crystalloid solution may be given followed by re-evaluation. 
These criteria identify patients at increased risk of death,23–25 and were found feasible and 
not associated with harm in the CLASSIC pilot trial.11 
2. In case of overt fluid losses (e.g. vomiting, large aspirates, diarrhoea, drain losses, 
bleeding or ascites tap). IV fluid may be given to correct for the loss, but not above 
the volume lost 
 
3. In case the oral/enteral route for water or electrolyte solutions is contraindicated or 
has failed as judged by the clinical team, IV fluids may be given to: 
o Correct dehydration or electrolyte imbalances 
o Ensure a total fluid input of 1L per 24 hours (fluids with medication and 
nutrition count as input) 
IV fluids may be given as carrier for medication, but the volume should be reduced to the 
lowest possible volume for the given medication. Oral/enteral fluids are not restricted in the 
IV fluid restriction group. 
 
Standard care group 
There will be no upper limit for the use of IV or oral/enteral fluids. In particular: 
 IV fluids should be given in the case of hypoperfusion or circulatory impairment and 
should be continued as long as hemodynamic variables improve including static or 
dynamic variable(s) as chosen by the clinicians. These criteria are based on the 
Surviving Sepsis Campaign guideline1 
 IV fluids should be given as maintenance if the ICU has a protocol recommending 
maintenance fluid 
 IV fluids should be given to substitute expected or observed loss, dehydration or 
electrolyte imbalances 
 
Outcome measures 
Primary outcome measure  
The primary outcome measure is all-cause mortality at day 90 after randomisation.  
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Secondary outcome measures   
We have 7 secondary outcome measures:  
 Number of participants with one or more serious adverse events (SAEs) in the ICU 
defined as ischaemic events (cerebral, cardiac, intestinal or limb ischaemia) or a new 
episode of severe AKI (modified KDIGO3 26) 
 Number of participants with one or more serious adverse reactions (SARs) to IV 
crystalloids in the ICU (Supplementary Appendix 5) 
 Days alive at day 90 without life support (vasopressor / inotropic support, invasive 
mechanical ventilation or renal replacement therapy (RRT)) 
 Days alive and out of hospital until day 90 
 All-cause mortality at 1 year after randomisation 
 Health-related quality of life (HRQoL) 1 year after randomisation measured using the 
EuroQoL EQ-5D-5L scores 27  
 Cognitive function 1 year after randomisation as assessed by the telephone MINI-
Montreal Cognitive Assessment (MINI-MoCA) score 28 
Detailed definitions of the outcome measures are available in Supplementary Appendix 4.  
 
Registered variables  
Baseline variables 
1. Sex  
2. Age 
3. Date of admission to hospital 
4. Date and time of the first ICU admission during the current hospitalisation 
5. From where the participant was admitted to ICU 
6. Focus of infection (pulmonary, gastrointestinal, urinary tract, skin or soft tissue or 
other infectious focus documented or suspected including meningitis, endocarditis, 
osteomyelitis, arthritis and bacteraemia) 
7. Co-morbidities prior to ICU admission (active hematological malignancy, metastatic 
cancer, ischemic heart disease or heart failure, chronic hypertension or chronic RRT) 
8. Blood values, interventions and vital parameters including participant weight, highest 
plasma lactate within 3 hours prior to randomisation, highest dose of noradrenaline 
within 3 hours prior to randomisation, volume of IV fluid 24 hours prior to 
randomisation, use of systemic corticosteroids 24 hours prior to randomisation, 
highest plasma creatinine value within 24 hours prior to randomisation, use of acute 
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RRT 3 days prior to randomisation and habitual plasma creatinine value prior to 
current hospitalisation 
9. Values for the Simplified Mortality Score in ICU (SMS-ICU),29 which is based on 7 
variables obtained within the 24 hours prior to randomisation (age, lowest systolic 
blood pressure, acute surgical admission, hematologic malignancy or metastatic 
cancer, and use of vasopressors/inotropes, respiratory support (invasive or non-
invasive mechanical ventilation) and RRT) 
Daily during ICU admission 
1. Fluid input and output cumulated from the 24-hour ICU charts  
- Total volume and specific type of IV isotonic crystalloids 
- Total volume of other IV fluids: e.g. <10% glucose 
- Total volume of albumin  
- Total volume of fluids with medications: both parenteral and enteral 
- Total volume of fluids with enteral and parenteral nutrition 
- Total volume of non-nutritional enteral/oral fluids 
- Total volume of blood products 
- Urinary output on this day 
- Any fluid volume removed during RRT 
- Total volume of other losses on this day including drainage, aspirates, stools and 
bleeding 
2. Major protocol violation on this day: 
- Restrictive group: IV fluids given without one of the extenuating circumstances on 
this day  
- Standard care group: the violations (no IV fluid given) will be assessed from all 
day form registrations regarding fluid input at the end of the trial  
3. Infusion of vasopressor or inotrope on this day   
4. Use of systemic corticosteroids on this day  
5. Use of invasive mechanical ventilation on this day  
6. Use of RRT on this day  
7. Plasma concentration of creatinine on this day 
8. Serious adverse events (SAEs) (at least one episode of either the following): 
- Ischemic events defined as either 
o Cerebral ischemia  
o Acute myocardial ischemia  
o Intestinal ischemia  
o Limb ischemia  
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- A new episode of severe AKI (defined as modified KDIGO3,26 Supplementary 
Appendix 4) 
9. Serious adverse reactions:  
- General tonic-clonic seizures 
- Anaphylactic reactions  
- Central pontine myelinolysis  
- Severe hypernatremia defined as p-Na >159 mmol/L 
- Severe hyperchloraemic acidosis defined as pH <7.15 AND p-chloride >115 
mmol/L 
- Severe metabolic alkalosis defined as pH >7.59 AND SBE >9 mmol/L  
Follow-up 90 days after randomisation 
1. Death (y/n, if yes date of death) 
2. Date of discharge from hospital 
3. Additional hospital admissions 
Follow-up 1 year after randomisation 
1. Death (y/n, if yes date of death) 
2. EQ-5D-5L and EQ-VAS score 
3. Telephone MoCA score 
Detailed definitions of the registered variables are available in Supplementary Appendix 6.  
Missing data  
If less than 5% of data required for any specific analysis on primary or secondary outcomes 
are missing, a complete case analysis will be performed. If more than 5% are missing, and it 
is concluded that data are not ‘missing completely at random’ (MCAR criterion),30,31 multiple 
imputation using chained equations will be performed by creating 25 input datasets under 
the assumption that the data are ‘missing at random’ (MAR criterion).32,33  
 
In any multiple imputation, we will use all relevant outcomes and the stratification variables 
(site and metastatic or hematologic cancer), SMS-ICU29 at baseline, site of infection at 
baseline, comorbidities at baseline (ischemic heart disease or heart failure, chronic 
hypertension or chronic RRT), use of corticosteroids at baseline, mechanical ventilation at 
baseline, highest p-creatinine 24 hours prior to randomisation, habitual p-creatinine, p-
lactate at baseline, participant weight at baseline, and volume of IV fluids given prior to 
randomisation. Multiple imputation will be performed separately in the two intervention 
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groups before pooling the full dataset, and the primary result of the trial will be based on 
these data. The unadjusted, non-imputed analysis will also be presented. If multiple 
imputation is used, we will also include a best-worst worst-best case scenario to assess the 
potential impact of any pattern of missingness including that data are ‘missing not at random’ 
(MNAR criterion). In the ‘best-worst-case’ scenario it is assumed that all participants lost to 
follow-up in the experimental group e.g. have survived; and that all patients with missing 
outcomes in the control group have not survived. Conversely, in the ‘worst-best-case’ 
scenario, it is assumed that all participants who were lost to follow up in the experimental 
group have had a harmful outcome; and that all those lost to follow-up in the control group 
have had a beneficial outcome. When continuous outcomes are used, a ‘beneficial outcome’ 
will be defined as the group mean plus two standard deviations (SD) of the group mean or 
highest possible value whichever is smallest, and a ‘harmful outcome’ will be defined as the 
group mean minus two SD of the group mean or lowest possible value whichever is highest. 
 
General analytical principles  
The analyses will be done in the intention-to-treat (ITT) population defined as all randomised 
participants for whom there is consent for the use of data. The conclusion of the trial will be 
based on the ITT analysis.  
The per-protocol population is defined as the ITT population except those having one or 
more major protocol violations. 
 
Statistical analyses  
Primary outcome 
Four analyses will be performed for the primary outcome:  
 
Primary analysis: 
1. Logistic regression analysis adjusted for the stratification variables34 (site and hematologic 
malignancy /metastatic cancer) in the ITT population. P-values will be two-tailed 
 
Sensitivity analyses: 
2. A two-tailed logistic regression analysis adjusted for the stratification variables, the SMS-
ICU29 focus of infection (other foci versus urinary tract infection)29,35 and use of 
corticosteroids36  
3. A two-tailed logistic regression analysis in the per-protocol population adjusted for the 
stratification variables  
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4. Two-tailed logistic regression analyses in the pre-planned subgroups adjusted for the 
stratification variables  
We will report absolute and relative risk ratios with 95% CIs for the primary analysis of the 
primary outcome (analysis 1) (P-value <0.05), computed using glm-models with appropriate 
link functions and binomial error-distribution. Further, we will report the crude event rates in 
each group and a Kaplan-Meier survival curve for the crude data of the primary outcome.  
Secondary outcomes 
Dichotomous secondary outcomes will be analysed in the same way as the primary analysis 
for the primary outcome, i.e.:  
 SAEs 
Two-tailed logistic regression adjusted for the stratification variables in the ITT 
population 
 SARs 
Two-tailed logistic regression adjusted for the stratification variables in the ITT 
population 
 1-year mortality 
Two-tailed logistic regression adjusted for the stratification variables in the ITT 
population 
 
A Kaplan-Meier survival curve will be reported for the crude data for secondary outcome 1-
year mortality. 
The remaining secondary outcomes are continuous measures which we expect to be 
skewed (non-normally distributed), because of inflation of specific values such as zero for 
‘days alive outside hospital’ for all patients who die while in the ICU. The outcome measures 
will be analysed as follows: 
 Days alive at day 90 without life support  
Generalised linear model or nonparametric test stratified for site in the ITT population  
 Days alive and out of hospital at day 90 
Generalised linear model or nonparametric test stratified for site in the ITT population 
 HRQoL 1-year after randomisation27 
Generalised linear model or nonparametric test stratified for site in the ITT population 
 Cognitive function 1-year after randomisation28 
Generalised linear model or nonparametric test stratified for site in the ITT population 
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For the generalised linear model we will initially use Poisson distribution, alternatively 
negative binomial.38 If the assumptions for Poisson distribution or negative binomial 
distribution are not met, data will be analysed using the nonparametric Van Elteren test 
adjusted for site, but no other variables.39 
The following secondary outcome measures are composite; SAEs, SARs, days alive at day 
90 without life support. We will report each component of these outcomes in an appendix to 
the primary publication without P-values due to the lack of adjustment for multiple 
comparisons.  
We will report absolute and relative risk ratios with 99% CIs for dichotomous secondary 
outcomes. For continuous secondary outcomes we will report mean differences with 99% 
CIs if they are normally distributed and medians with 99% percentile-based bootstrapped CIs 
for non-normally distributed continuous secondary outcomes (P-value 0.01) due to the 
multiplicity of these. Definition of the level of significance for the secondary outcomes is 
available in Supplementary Appendix 7.  
Sample size  
Primary outcome 
We plan to enrol 1554 (2 x 777) patients to be able to show a 15% relative risk-reduction 
(RRR) (7% absolute) in the restrictive group on the primary outcome from an estimated 45% 
90-day mortality in the standard care group at type 1 and 2 error levels of 5% and 20% 
respectively, corresponding to a number needed to treat (NNT) of 14 or less. The anticipated 
relative risk reduction of mortality and the estimated mortality in the control group is based 
on data from previous RCTs and systematic reviews.11,40–43 
Trial sequential analysis of existing trials (n=8) have shown that less than 15% of the 
required information size of 3956 patients to detect or reject a 15% RRR in all-cause 
mortality with lower versus higher fluid volumes has been reached. (Meyhoff 2019, in 
preparation).16 
Secondary outcomes 
We expect to have the following statistical power for the secondary outcomes based on 2 x 
777 participants, a type 1 error level of 1% and a RRR of 15% in the fluid restriction group 
versus standard care group: 
 
- 50% power for the number of participants with one or more SAEs (control event rate 25% 
40,41) 
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- 10% power for the number of participants with one or more SARs (control event rate 
5%40,41) 
- 80% power for the mortality at 1-year (control event rate 55%40,41) 
The estimates of the control event rates originate from data of previous septic shock trials.  
 
We expect the following outcomes to be highly skewed (non-normally distribution): days 
alive without life support and out of hospital at day 90 and HRQoL and cognitive function at 1 
year. As we lack sufficient knowledge on the details of the non-normal distribution no 
realistic power analysis can be provided. We therefore refrain from this in order to avoid 
creating a false impression of precision. 
 
Pre-planned subgroup analyses  
We plan to assess heterogeneity of intervention effects of the primary outcome in the 
following 5 subgroup analyses based on patient characteristics at baseline:  
1. Respiratory support at randomisation (hypothesised increased effect of fluid 
restriction in patients receiving respiratory support) 
2. Severe AKI defined as modified KDIGO2 or above26 at randomisation (hypothesised 
increased effect of fluid restriction in patients with severe AKI)26 
3. Severe metabolic failure at randomisation defined as plasma lactate level above 4 
mmol/l (hypothesised increased effect of fluid restriction in patients with severe 
metabolic failure) 
4. Participant weight at randomisation with higher weight defined as bodyweight 
(measured or estimated) ≥76 kg11,40,41 versus lower weight as <76 kg (hypothesised 
increased effect of fluid restriction in patients with lower weight)  
5. Patients who received ≥30ml/kg body weight IV fluids in the 24 hours prior to 
randomisation versus patients who received a lower volume (hypothesised increased 
effect of fluid restriction in patients with less fluids given 24 hours prior to 
randomisation) 
6.  
For all subgroups a P-value <0.01 in the test of interaction will be considered statistically 
significant. Detailed definitions of the subgroups analysis is provided in Supplementary 
Appendix 8. 
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Trial profile  
At trial completion, the flow of trial participants will be reported according to the Consolidated 
Standards of Reporting Trials (CONSORT) statement.44 
Data Monitoring and Safety Committee  
A Data Monitoring and Safety Committee (DMSC) has been formed, consisting of 
independent ICU trialists/clinicians and a biostatistician who collectively have experience in 
the management of ICU patients and in the conduct, monitoring and analysis of RCTs. The 
charter for the DMSC is available from Supplementary Appendix 9.  
 
Interim analyses  
We will perform 3 interim analyses:  
 
1. Interim analysis when 10% of patients have completed 30-days follow-up  
2. Interim analysis when 30% of patients have completed 30-days follow-up  
3. Interim analysis when 50% of patients have completed 90-days follow-up  
For the first two interim analyses the DMSC will evaluate data on: 
 Fluid volumes and protocol violations 
For the third interim analysis the DMSC will evaluate data on:  
 Fluid volumes, protocol violations, 90-day mortality and rates of SAEs and SARs in 
the ICU 
The DMSC will be provided with the following masked (as group 0 and 1) data from the 
coordinating centre: 
 Number of patients randomised 
 Number of patients randomised per intervention group 
 Number of patients stratified per stratification variable per intervention group 
 Number of events, according to the outcomes, in the two groups  
Based on evaluation of these outcomes, the DMSC will decide if they want further data from 
the coordinating centre. The DMSC can, at any time during the trial, request the distribution 
of events, including outcome measures and SARs according to intervention groups. Further, 
the DMSC can request unblinding of the interventions.  Additionally, the DMSC will yearly be 
informed about SARs in the two groups of the trial. 
The interim analyses will be performed by an independent statistician. The DMSC may 
recommend pausing or stopping the trial if a group-difference in the primary outcome 
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measure, SARs or SUSARs are found in the interim analyses with statistical significance 
levels adjusted according to the LanDeMets group sequential monitoring boundaries based 
on O’Brien Fleming alfa-spending function.45 If the recommendation is to stop the trial, the 
DSMC will discuss and recommend on whether the final decision to stop the trial will be 
made after the analysis of all participants included at the time (including participants 
randomized after participant number 777) and whether a moratorium shall take place (setting 
the trial at hold) in the further inclusion of participants during these extra analyses. If further 
analyses of the participants included after 777 participants is recommended, the rules for 
finally recommending stopping of the trial should obey the LanDeMets stopping boundary. 
Furthermore, the DMSC can recommend pausing or stopping the trial if continued conduct of 
the trial clearly compromises participant safety. The Management Committee will make the 
final decision regarding the continuing, pausing or stopping of the trial. However, stopping for 
futility to show an intervention effect of 15% RRR or RRI will not occur, as intervention 
effects <15% RRR or RRI in all-cause mortality may be clinically relevant. 
 
DISCUSSION 
The optimal strategy for IV fluid therapy in adults with septic shock is largely unknown, and 
existing data on lower versus higher fluid volumes is of low/very low quality.  
Together with existing data, and data from other on-going RCTs,46,47 the CLASSIC trial will 
provide important knowledge on the use of lower versus higher IV fluid volumes in adult ICU 
patients with septic shock.  
Strengths  
Prior to initiation of the CLASSIC trial, we have assessed current evidence in a systematic 
review16 and the feasibility of the fluid protocol in an international pilot RCT.11  
The CLASSIC trial is a large international trial designed to provide data on the effect of fluid 
volumes on patient-important outcomes with the lowest possible risk of bias. The trial is 
monitored according to the standards of GCP.19 The trial design is pragmatic with all other 
treatments than fluid therapy following routine practice to increase external validity. Prior to 
data analysis, we will publish this protocol and statistical analysis plan paper, including 
detailed power estimations. Finally, we report several secondary outcomes as composite 
outcomes to increase the power. As we will include 1554 patients with septic shock, we 
expect that our trial together with other on-going RCTs46,47 will provide data to increase the 
acquired information and getting closer to the required information size of 3956 patients 
estimated so far by trial sequential analysis. (Meyhoff 2019, in preparation)16 
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Limitations 
The CLASSIC trial intervention is not masked for investigators, clinicians and patients, as 
blinding of different fluid strategies is not feasible. This increases the risk of bias,48,49 in 
particularly it may affect the clinicians behaviour regarding fluid administration over the 
course of the trial. Current practice of IV fluid therapy may already be changing without firm 
evidence. Therefore, we will conduct two early interim analyses assessing IV fluid volumes 
in the two groups, enabling the Management Committee to act to ensure separation in fluid 
volumes between the two groups during the trial. Also, our primary outcome is 90-day 
mortality, which may be less likely to be affected by lack of blinding in RCTs,50 although 
conflicting data exist.51   
Our trial participants may be subjected to protocol violations, expected to occur more 
frequently in the restrictive group. In general, protocol violations may be more frequent in 
trials of complex interventions in ICU.11,40,41,52 In the CLASSIC pilot trial, a difference in 
resuscitation fluid volumes was observed despite protocol violations.11 Further, there was no 
indication of safety concerns in that trial, why we will encourage trial site staff to administer 
IV fluids in accordance with the protocol.  
In conclusion, the CLASSIC trial is a large European trial assessing the effects of IV fluid 
restriction versus standard care on patient-important outcome measures in adult ICU 
patients with septic shock. The trial results will provide important evidence to guide 
intravenous fluid therapy in this critically ill population. 
Ethical considerations and consent to participate  
The CLASSIC trial is registered at the European Clinical Trials Database (2018-000404-42) 
and  www.clinicaltrials.gov (NCT03668236), is approved by the Danish Medicines Agency 
(2018020596), the Danish National Committee on Health Research Ethics (H-18006255), 
and the Danish Data Protection Agency (VD-2018-392).  
Data sharing statement 
The final de-identified dataset used for analysis will be made publicly available 9 months 
after the publication of the outcome data according to the recent ICMJE recommendations.53 
All trial-related documents are available from www.cric.nu/CLASSIC  
 
Dissemination 
After completion of the CLASSIC trial, all trial results will be submitted to a peer-reviewed 
medical journal irrespective of the direction of the results. Further, the trial results will be 
published at www.cric.nu. We will adhere to the CONSORT statement including the 
accountability of all patients screened.44 
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Status 
The Trial was initiated on November 27th 2018 and is expected to be completed within 2 
years.  
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